KarRC RAS
in social media
in social media
Publications
Scientific publications
Дуданова О. П., Белавина И. А., Курбатова И. В., Ларина А. А., Топчиева Л.В.
Эффективность применения урсодезоксихолевой кислоты при неалкогольном стеатогепатите
// Экспериментальная и клиническая гастроэнтерология. Вып. 123, №11. 2015. C. 10-14
Dudanova O.P., Belavina I.A., Kurbatova I.V., Larina A.A. , Topchieva L.V. Efficiency of ursodeoxycholic acid application in nonalcocholic steatohepatitis // Clinical and Experimental Gastroenterology. Vol. 123. № 11. 2015. Pp. 10-14
Keywords: ursodeoxycholic acid, nonalcocholic steatohepatitis, apoptosis, kaspase genes, liver blood flow
Aim: to estimate the efficiency of ursodeoxycholic acid (UDHC) in nonalcocholic steatohepatitis (NASH) by analysis of conventional clinical datas, apoptosis and liver perfusion parameters.
Materials and methods: UDHC was used as monotherapy in treatment of 92 NASH patients in daily dose 10–15 mg/kg. We have observed 44 (47.8%) males, 48 (52.2%) females, age was 56.8±7.2 years, BMI was 28.4±2.3 kg/m2, waist circumference was 93,8±8,3 сm. Functional liver tests (ALAT, ASAT, alcaline phosphatase — APh, gamma‑glutamyltranspeptidase —
GGTP), abdominal ultrasonography and dopplerography of liver blood flow, kaspase‑3, 6, 8, 9 genes expression in blood leucocytes were estimated. Periods of controls research and UDCA treatment were: 4–8 weeks in 92 patients, 20–24 weeks in 18 (19.6%) patients and 40–48 weeks in 13(14.1%) patients.
Results. Significant positive dynamics of liver functional tests and decrease of kaspase‑3, 6, 9 genes expression in blood leucocytes were observed over 4–8 weeks, normalization of liver tests — over 20–24 weeks and significant amelioration of venous and arterial liver perfusion parameters — over 40–48 weeks.
Conclusion. Ursodeoxycholic acid in daily dose of 10–15 mg/kg in nonalcocholic steatohepatitis caused positive dynamics of cytolytic and cholestasis parameters, leucocytic apoptosis and venous and arterial liver blood flow parameters
Materials and methods: UDHC was used as monotherapy in treatment of 92 NASH patients in daily dose 10–15 mg/kg. We have observed 44 (47.8%) males, 48 (52.2%) females, age was 56.8±7.2 years, BMI was 28.4±2.3 kg/m2, waist circumference was 93,8±8,3 сm. Functional liver tests (ALAT, ASAT, alcaline phosphatase — APh, gamma‑glutamyltranspeptidase —
GGTP), abdominal ultrasonography and dopplerography of liver blood flow, kaspase‑3, 6, 8, 9 genes expression in blood leucocytes were estimated. Periods of controls research and UDCA treatment were: 4–8 weeks in 92 patients, 20–24 weeks in 18 (19.6%) patients and 40–48 weeks in 13(14.1%) patients.
Results. Significant positive dynamics of liver functional tests and decrease of kaspase‑3, 6, 9 genes expression in blood leucocytes were observed over 4–8 weeks, normalization of liver tests — over 20–24 weeks and significant amelioration of venous and arterial liver perfusion parameters — over 40–48 weeks.
Conclusion. Ursodeoxycholic acid in daily dose of 10–15 mg/kg in nonalcocholic steatohepatitis caused positive dynamics of cytolytic and cholestasis parameters, leucocytic apoptosis and venous and arterial liver blood flow parameters
Indexed at Scopus, RSCI
Last modified: March 22, 2017